-
Ascletis Pharma’s ASC47 Shows Positive Results in Phase Ib Study for Weight Loss
•
China-based Ascletis Pharma Inc. (HKG: 1672) announced positive topline results from a Phase Ib clinical study of its ASC47 in Australia. This adipose-targeted drug candidate, developed in-house, is designed to achieve weight loss without losing muscle mass. Clinical Study ResultsIn the study, ASC47 demonstrated a half-life of up to 26…
-
Ascletis Pharma’s ASC47 Outperforms Semaglutide in Weight Loss Study
•
China-based Ascletis Pharma Inc. (HKG: 1672) has announced encouraging results from a study on its in-house developed drug candidate, ASC47, which is designed to achieve weight loss without compromising muscle mass. The study combined ASC47 with semaglutide in a diet-induced obesity (DIO) mouse model, demonstrating superior weight loss effects compared…
-
Ascletis Pharma’s ASC47 Showcases Promising Weight Loss Results in Phase I Clinical Trial
•
Ascletis Pharma Inc. (HKG: 1672), a China-based pharmaceutical company, has announced positive results from a Phase I clinical study for its drug candidate ASC47 in Australia. This in-house developed therapy is designed to facilitate weight loss without the loss of muscle mass, offering a potential new option for obesity management.…
-
Ascletis Pharma Faces US Import Ban for NASH Drugs ASC41 and ASC43F in Trade Secrets Dispute
•
China’s Ascletis Pharma Inc. (HKG: 1672) is navigating legal proceedings involving its oral thyroid hormone receptor-beta (THRβ) agonist ASC41 and a compound preparation ASC43F, both under development for the treatment of non-alcoholic steatohepatitis (NASH). US-based Viking Therapeutics (NASDAQ: VKTX) filed a lawsuit in the United States against Ascletis in December…
-
Ascletis Pharma’s ASC40 Earns FDA Breakthrough Therapy Designation for Fibrotic MASH
•
China-based Ascletis Pharma Inc. (HKG: 1672) has announced that ASC40 (denifanstat), a fatty acid synthase (FASN) inhibitor co-developed with US partner Sagimet Biosciences Inc. (NASDAQ: SGMT), has received a breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA). The designation is for the treatment of patients with…
-
Ascletis Pharma Initiates Phase I Trials for Monthly Subcutaneous and Daily Oral Obesity Treatment ASC30 in the US
•
Ascletis Pharma Inc. (HKG: 1672), a biopharmaceutical company based in China, has announced the dosing of the first batch of patients in two Phase I clinical studies for its investigational drug ASC30 in the United States. ASC30 is positioned as the world’s first and only small molecule glucagon-like peptide-1 receptor…
-
Ascletis Pharma’s ASC41 Shows Promise in Phase II Study for Metabolic Dysfunction-Associated Steatohepatitis
•
Ascletis Pharma Inc. (HKG: 1672), a biopharmaceutical company based in China, has announced positive interim results from a 12-week Phase II clinical study of its thyroid hormone receptor β (THRβ) agonist, ASC41, in patients with metabolic dysfunction-associated steatohepatitis (MSAH). The randomized, double-blinded, placebo-controlled, and multi-center Phase II trial demonstrated significant…
-
Ascletis Pharma Halts ASC42 Phase II Study in Primary Biliary Cholangitis
•
China-based Ascletis Pharma Inc. (HKG: 1672) has announced its decision to terminate the Phase II clinical study for ASC42 in primary biliary cholangitis (PBC) following a comprehensive data analysis. The farnesoid X receptor (FXR) agonist will also see the cancellation of studies in non-alcoholic steatohepatitis (NASH) and hepatitis B virus…
-
Ascletis Pharma’s ASC41 Shows Promising Results in Phase II NASH Study
•
Ascletis Pharma Inc. (HKG: 1672), a Chinese pharmaceutical company, has announced positive interim results from a 52-week Phase II study evaluating the efficacy of the thyroid hormone receptor β (THRβ) agonist ASC41 in patients with liver biopsy-proven non-alcoholic steatohepatitis (NASH). The ongoing, randomized, double-blind, placebo-controlled, and multi-center Phase II study…
-
Ascletis Pharma’s Denifanstat Advances to Phase III for Severe Acne Vulgaris Treatment
•
Ascletis Pharma Inc., (HKG: 1672) a China-based biotechnology company, has announced the commencement of a Phase III trial for its drug candidate denifanstat (ASC40), intended to assess its efficacy in treating severe acne vulgaris. The trial, a randomized, double-blind, placebo-controlled, and multi-center study, will be conducted at hospitals across China,…
-
Ascletis Pharma Inc. Reports 21.7% Revenue Increase in H1 2023, Led by Ritonavir Sales
•
China-based Ascletis Pharma Inc., (HKG: 1672) has revealed revenues of RMB 46.51 million (USD 6.38 million) for the first half of 2023, marking a 21.7% increase year-on-year. The significant growth was primarily driven by Ritonavir, which contributed RMB 44.17 million, representing a substantial 6291.8% YOY increase. Ritonavir’s Impact and Pfizer…
-
Ascletis Pharma’s ASC22 Combo Therapy Shows Promise in HIV Functional Cure Clinical Trial
•
China-based Ascletis Pharma Inc., (HKG: 1672) has announced that the Shanghai Public Health Clinical Center presented clinical results of ASC22 (envafolimab) in combination with chidamide as a novel combination therapy aimed at achieving a functional cure for human immunodeficiency virus (HIV) infection. The findings were showcased at the 12th International…
-
Ascletis Pharma Receives Approval for Phase IIa Study of ASC10 for RSV Infection
•
China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving the green light to conduct a Phase IIa study for its ASC10 in the treatment of respiratory syncytial virus (RSV) infection. This follows the company’s previous approval from the US FDA in January 2023 to carry out a similar Phase IIa…
-
Ascletis Pharma’s ASC40 Meets Acne Treatment Goals in Phase II Trial
•
China-based Ascletis Pharma Inc. (HKG: 1672) has announced that its first-in-class, once-daily oral fatty acid synthase (FASN) inhibitor, ASC40 (senifanstat), has successfully met primary and key secondary endpoints in a Phase II clinical trial for acne vulgaris. ASC40’s Mechanism of Action and Trial DesignASC40 is an oral, selective small-molecule inhibitor…
-
Ascletis Pharma’s ASC10 Shows Promising Phase I Results at CROI 2023
•
China-based Ascletis Pharma Inc. (HKG: 1672) has announced positive results from a Phase I clinical study for its oral double prodrug ASC10. The findings were presented at the CROI 2023 annual meeting, marking a significant step forward in the development of this promising therapeutic candidate. Phase I Clinical Data HighlightsThe…
-
Ascletis Receives FDA Approval for Phase IIa Trial of ASC10 in RSV Infection
•
China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving approval from the US FDA to conduct a Phase IIa clinical study for its investigational drug ASC10 in patients with respiratory syncytial virus (RSV) infection. ASC10 is an oral double prodrug designed to be rapidly and completely converted in vivo into…
-
Ascletis Receives IND Approval for ASC10 in Monkeypox Treatment
•
China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA) for its ASC10, an oral double prodrug antiviral, to evaluate its potential as a treatment for monkeypox. This approval marks a significant step in expanding the therapeutic applications of…
-
Ascletis Partners with Simcere for Ritonavir Supply in COVID-19 Drug Development
•
China-based Ascletis Pharma Inc. (HKG: 1672) has announced that its wholly-owned subsidiary Ascletis Pharmaceuticals Co., Ltd has entered into a supply agreement for ritonavir tablets with Hainan Simcere Pharmaceutical Co., Ltd, a subsidiary of Simcere Pharmaceutical Group Limited (HKG: 2096). This partnership aims to support the development and supply chain…
